Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00796
|
|||||
| Drug Name |
Clemastine
|
|||||
| Synonyms |
(+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin; CLEMASTINE FUMARATE; Clemastina; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum; Clemastinum [INN-Latin]; HS 592; HS-592; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavegyl (TN); Tavist; Tavist (*Fumarate*); Tavist (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Therapeutic Class |
Antiallergic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H26ClNO
|
|||||
| Canonical SMILES |
CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C
|
|||||
| InChI |
InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
|
|||||
| InChIKey |
YNNUSGIPVFPVBX-NHCUHLMSSA-N
|
|||||
| CAS Number |
CAS 15686-51-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 343.9 | Topological Polar Surface Area | 12.5 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
5
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.